Why Surrozen, Inc.’s (SRZN) Stock Is Down 5.61%
As of Monday, July 13, Surrozen, Inc.’s SRZN share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Surrozen, Inc.’s (SRZN) Stock Is Down 5.74%
As of Friday, July 10, Surrozen, Inc.’s SRZN share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Michael Rose
Why Surrozen, Inc.’s (SRZN) Stock Is Down 5.54%
As of Tuesday, July 07, Surrozen, Inc.’s SRZN share price has dipped by 5.54%, which has investors questioning if this is right time to buy.Michael Rose
Why Surrozen, Inc.’s (SRZN) Stock Is Up 11.16%
As of Wednesday, June 17, Surrozen, Inc.’s SRZN share price has surged by 11.16%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Surrozen, Inc.’s (SRZN) Stock Is Up 9.47%
As of Wednesday, June 17, Surrozen, Inc.’s SRZN share price has surged by 9.47%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $241.8 | $251.9 | 29% |
|
| Shares Out (Mil) | 10.9 | 50.8 | 22% |
|
| Institutional Ownership | 98.7% | 92.0% | 81% |
|
| Float (Mil) | 5.4 | 40.5 | 13% |
|
| Beta | 0.59 | 0.95 | 34% |
|
| Avg Daily Volume (000s) | 297 | 447 | 51% |
|
| Price Change (52-week) |
125.2% | 54.2% | 94% |
|
| Growth | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | (49.2%) | (9.8%) | 7% |
|
| EPS (5yr) | (1.0%) | 16.3% | 29 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 5.8% | (15.6%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 2 | |
| Current EPS | ($1.260) | ($12.090) | ($3.985) | |
| Month Ago EPS | ($1.260) | ($12.090) | ($3.985) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($1.110) | ($3.700) | ($3.565) | |
| Year/Year Chg | (89.2%) | (62.6%) | (87.4%) | |
| Financials | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $39 | 8% |
|
| Net Income (TTM) (Mil) | ($343) | ($43) | 4% |
|
| EPS (TTM) | ($36.802) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($30) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $3 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $5 | 24% |
|
| Enterprise Value (Q1) (Mil) | $204 | $182 | 26% |
|
| Valuation | SRZN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.60 | na |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SRZN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (328.8%) | 63.8% | 1% |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (290.9%) | (49.7%) | 1% |
|
| ROE | 251.4% | (55.4%) | 98% |
|
| Liabilities to Assets | 330.4% | 30.3% | 100% |
|
| F-Score | 3 | 3 | 19% |
|
Surrozen, Inc. did not pass any screens on 7/30/2026.
